Eli Lilly and Company (NYSE:LLY – Get Rating) CAO Donald A. Zakrowski sold 600 shares of Eli Lilly and stock in a transaction that occurred on Monday, May 15th. The shares were sold at an average price of $435.29, for a total transaction of $261,174.00. Following the completion of the transaction, the chief accounting officer now owns 5,978 shares of the company’s stock, valued at approximately $2,602,163.62. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Eli Lilly and Stock Up 0.1 %
Shares of NYSE:LLY opened at $437.89 on Friday. The company has a market capitalization of $415.68 billion, a PE ratio of 69.62, a P/E/G ratio of 2.33 and a beta of 0.37. The company has a current ratio of 1.30, a quick ratio of 1.02 and a debt-to-equity ratio of 1.67. Eli Lilly and Company has a twelve month low of $283.11 and a twelve month high of $445.54. The firm has a 50 day simple moving average of $375.60 and a 200-day simple moving average of $359.57.
Eli Lilly and (NYSE:LLY – Get Rating) last issued its quarterly earnings data on Thursday, April 27th. The company reported $1.62 earnings per share for the quarter, missing the consensus estimate of $1.73 by ($0.11). The company had revenue of $6.96 billion for the quarter, compared to analysts’ expectations of $6.87 billion. Eli Lilly and had a return on equity of 61.42% and a net margin of 20.54%. The firm’s quarterly revenue was down 10.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.62 EPS. On average, equities analysts predict that Eli Lilly and Company will post 8.78 EPS for the current fiscal year.
Eli Lilly and Announces Dividend
Institutional Trading of Eli Lilly and
Several institutional investors and hedge funds have recently bought and sold shares of the business. Guardian Wealth Advisors LLC purchased a new stake in Eli Lilly and in the 1st quarter valued at $105,000. Border to Coast Pensions Partnership Ltd raised its position in Eli Lilly and by 20.2% in the 1st quarter. Border to Coast Pensions Partnership Ltd now owns 138,519 shares of the company’s stock valued at $47,570,000 after purchasing an additional 23,284 shares during the last quarter. Harvest Portfolios Group Inc. raised its position in Eli Lilly and by 24.5% in the 1st quarter. Harvest Portfolios Group Inc. now owns 157,517 shares of the company’s stock valued at $54,094,000 after purchasing an additional 30,969 shares during the last quarter. B. Riley Wealth Advisors Inc. raised its position in Eli Lilly and by 15.2% in the 1st quarter. B. Riley Wealth Advisors Inc. now owns 45,700 shares of the company’s stock valued at $15,694,000 after purchasing an additional 6,027 shares during the last quarter. Finally, Advisory Services Network LLC raised its position in Eli Lilly and by 4.3% in the 1st quarter. Advisory Services Network LLC now owns 48,012 shares of the company’s stock valued at $16,488,000 after purchasing an additional 1,972 shares during the last quarter. Hedge funds and other institutional investors own 82.13% of the company’s stock.
Wall Street Analyst Weigh In
LLY has been the subject of a number of research reports. Societe Generale cut shares of Eli Lilly and from a “hold” rating to a “sell” rating and set a $278.00 price objective for the company. in a report on Wednesday, February 15th. Credit Suisse Group lifted their price objective on shares of Eli Lilly and from $420.00 to $490.00 in a report on Thursday, May 4th. Jefferies Financial Group lifted their price objective on shares of Eli Lilly and from $290.00 to $310.00 and gave the company a “hold” rating in a report on Monday, April 3rd. UBS Group boosted their price target on shares of Eli Lilly and from $438.00 to $447.00 in a report on Friday, April 28th. Finally, Citigroup lowered their price target on shares of Eli Lilly and from $370.00 to $360.00 and set a “buy” rating for the company in a report on Friday, March 3rd. One research analyst has rated the stock with a sell rating, two have issued a hold rating and twelve have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $415.75.
Eli Lilly and Company Profile
Eli Lilly & Co engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm’s products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
Featured Articles
- Get a free copy of the StockNews.com research report on Eli Lilly and (LLY)
- It’s Time To Take Another Bite Of Take-Two Interactive
- Zoetis Declares New Dividend, Hinting At Undervaluation
- Good News For Walmart Isn’t So Great For Everybody Else
- Eagle Materials, Answering America’s Building Supply Needs
- Pharma Giants Novartis, Lilly, Merck, and Novo Outperform Market
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.
